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Influenza A virus (IAV) and influenza B virus (IBV) cause substantial morbidity and mortality during annual epidemics. Two distinct 
lineages of IBV are distinguished, based on variation in hemagglutinin (HA): B/Victoria/2/87-like (B/Vic) and B/Yamagata/16/88-
like (B/Yam). Here, we show that, in humans, primary IBV infection with either lineage induces HA-specific antibody-dependent 
cellular cytotoxicity (ADCC)–mediating antibodies. IBV infection induced antibodies specific to the HA head and stalk, but only 
HA stalk–specific antibodies mediated ADCC efficiently and displayed cross-reactivity with IBV of both lineages. This corresponds 
to recent findings that 2 points of contact between the effector and target cell (ie, HA and sialic acid, respectively, and the fragment 
crystallizable [Fc] domain and Fcγ receptor IIIα, respectively) are required for efficient ADCC activity and that antibodies specific 
for the receptor-binding site located in the head domain of HA therefore fail to mediate ADCC. Potentially, ADCC-mediating anti-
bodies directed to the HA stalk of IBV contribute to cross-protective immunity to IBV of both lineages.
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Influenza viruses cause 3–5 million cases of severe illness and half 
a million deaths worldwide per year during annual epidemics [1]. 
Cocirculating influenza A viruses (IAV; subtypes H1N1 and H3N2) 
and influenza B virus (IBV) are responsible for this morbidity and 
mortality. Like IAV, IBV displays antigenic drift by accumulating 
mutations in the gene encoding hemagglutinin (HA), resulting in 
viral escape from recognition by neutralizing antibodies induced 
by previous infections or vaccinations [2–4]. However, antigenic 
drift of IBV is less pronounced than that of IAV [5].
IBV possesses 2 major surface glycoproteins, HA and neur-
aminidase (NA). Based on antigenic and genetic variation of 
HA, 2 distinct lineages of IBV that cocirculate globally are dis-
tinguished, the B/Victoria/2/87-like (B/Vic) lineage and the B/
Yamagata/16/88-like (B/Yam) lineage [6–8]. The earliest IBV 
isolate originates from the 1940s [9], and it is currently thought 
that the 2 lineages diverged in the 1970s [2, 6, 10, 11]. Although 
the IBV lineages are often compared to the different IAV sub-
types, the homology of the HA amino acid sequence between 
the 2 lineages of IBV is higher than between the 2 subtypes of 
seasonal IAV [7].
The primary protective measure against IBV infection is 
vaccination. Currently used seasonal influenza vaccines aim 
to induce virus-neutralizing antibodies directed to the variable 
head domain of HA and are mainly trivalent inactivated vaccines, 
which contain IBV of a single lineage, in addition to influenza 
A(H1N1) and A(H3N2) components. However, IBV lineage 
mismatches between circulating IBV strains and the strains used 
for trivalent inactivated vaccine production frequently occur 
[12–14]. Notably, in the 10 seasons between 2001–2002 and 
2010–2011, the IBV lineage selected for inclusion in the seasonal 
TIV only matched the dominant circulating IBV lineage 5 times, 
with the lineage of 46% and 58% of strains not represented in 
the vaccine in the United States and Europe, respectively [12, 
14]. Vaccine effectiveness is significantly higher against a vac-
cine-matched IBV strain than against a strain from the opposing 
lineage, proving that vaccine-induced antibodies cross-neutralize 
poorly and that the 2 lineages are antigenically distinct [14–16]. 
The difficulty of predicting which IBV lineage will circulate in 
the coming season, combined with limited cross-reactivity in the 
case of a vaccine mismatch, forms the basis for the rationale to 
include IBVs of both lineages in quadrivalent seasonal vaccines.
Virus-specific antibodies are induced upon natural infec-
tion with or vaccination against IBV. Antibodies directed to 
antigenic sites in or around the receptor-binding site located 
in the head domain of HA have the capacity to directly neu-
tralize IBV. In addition to direct neutralization, virus-specific 
antibodies can have other modes of action, in particular those 
of the immunoglobulin G1 (IgG1) and IgG3 subclasses [17]. 
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After antibody binding to antigens displayed on virus-infected 
cells, the fragment crystallizable (Fc) domain of these anti-
bodies engages Fc receptors on host effector cells that subse-
quently kill virus-infected cells through antibody-dependent 
cellular cytotoxicity (ADCC) [18, 19], antibody-dependent 
phagocytosis [20, 21], or complement-dependent cytotoxicity 
[22]. Specifically, ADCC is predominantly induced by inter-
action between the Fc region of virus-specific antibodies and 
Fcγ receptor IIIα (FcγRIIIα; also known as CD16), present on 
natural killer (NK) cells. IAV-specific monoclonal antibodies 
directed to the conserved HA stalk domain were shown to have 
protective efficacy through Fcγ receptor–dependent mecha-
nisms in mice [19, 23, 24].
Here, we analyzed the presence of functional HA-specific 
ADCC-mediating antibodies in serum samples obtained from 
children after primary infection with IBV from either lineage. 
Using recombinant full-length HA from both lineages in sol-
id-phase ADCC assays, we demonstrated that primary IBV 
infection induces HA-specific ADCC-mediating antibodies and 
that these antibodies cross-reacted with HA from IBV of the 
opposing lineage. By using both the HA1 subunit of HA and a 
chimeric HA protein that contains only the stalk region of IBV, 
we showed that cross-lineage reactive antibodies were directed 
to the HA stalk. Furthermore, IBV HA head–specific antibodies 
present in human sera were not capable of mediating ADCC.
METHODS
Ethics Statement
Serum samples were obtained from healthy volunteers and sub-
jects enrolled in another study (ie, the PIENTER 2 study) [25]. 
The Medical Ethical Committee of University Hospital, Erasmus 
Medical Center (MEC-2015–095), approved the collection of blood 
specimens from healthy volunteers; all participants gave informed 
consent and permission for use of materials. The work described 
has been carried out in accordance with the code of ethics of the 
World Medical Association (ie, the Declaration of Helsinki).
Study Subjects
Healthy Volunteers
Pilot experiments, assay setup, and end point titrations were 
performed with serum samples from healthy coworkers from 
the Erasmus Medical Center Department of Viroscience. 
Coworkers had received trivalent influenza vaccine at least once 
in previous years.
PIENTER 2 Participants
Serum samples were collected during a nationwide, cross-sec-
tional, population-based study performed in the Netherlands 
from February 2006 to June 2007 (ie, the PIENTER 2 study) 
[25, 26]. For the study described here, 41 serum samples were 
selected from children 1–7  years of age who did not receive 
influenza vaccination (1:1 ratio of samples to children). The 
numbers of samples from children who were 1, 2, 3, 4, 5, 6, and 
7 years of age were 3, 5, 5, 5, 6, 10, and 7, respectively. HI titers 
against multiple representative IAV and IBV strains (circulating 
or in vaccines between 1999–2000 and 2006–2007) were deter-
mined in the scope of another study [25]. Based on HI data, 
18 subjects were categorized as B/Vic responders, and 23 were 
categorized as B/Yam responders (Tables 1 and 2). B/Vic and B/
Yam responders were defined as individuals with HI antibodies 
against viruses of the corresponding lineage and the absence of 
antibodies against the opposing lineage.
Detection of HA-Specific Antibodies by Enzyme-Linked Immunosorbent 
Assay (ELISA)
Ninety-six–well enzyme immunoassay/radioimmunoassay 
plates (Greiner) were coated overnight at 4°C with 50 ng/
well of full-length HA derived from B/Yamanashi/166/98 (B/
Yam-lineage) or B/Brisbane/60/08 (B/Vic-lineage), the HA1 
subunit derived from B/Florida/4/06 (B/Yam-lineage) or B/
Malaysia/2506/04 (B/Vic-lineage) or chimeric HA, contain-
ing the stalk of IBV B/Yamagata/16/88 and the head domain 
of the IAV A/mallard/Sweden/24/02 (cH8/B) [27] in 0.05 M 
carbonate/bicarbonate buffer (pH 9.6; Sigma Aldrich; Figure 
1). Plates were blocked for 1 hour at room temperature, using 
phosphate-buffered saline (PBS) with 0.05% Tween (PBST; pH 
7.2; Thermo Fisher Scientific) supplemented with 2% (w/v) milk 
powder (Semper). A 5-fold dilution series of serum samples was 
prepared in blocking buffer starting at 1:40 and incubated on the 
coated plates for 1 hour at room temperature. A positive con-
trol (serum from an individual with a strong response to IBV) 
and negative controls (pooled sera from influenza virus–naive 
children; positive and negative controls were on antigen-coated 
plates) were included. In addition, mock-coated plates were 
used as negative control. Plates were washed with PBST and 
incubated with anti-human IgG horseradish peroxidase for 1 
hour at room temperature. Subsequently, plates were washed 
with PBST, and 3,3ʹ,5,5ʹ-tetramethylbenzidine peroxidase sub-
strate (Svanova Biotech) was added. Reactions were stopped 
with 1.8 M H2SO4, and absorbance was measured at 450 nm 
by using a SpectraMax Plus 384 Microplate Reader (Molecular 
Devices). End point titers were determined as the reciprocal of 
the highest dilution at which the OD450 was below background 
(defined as 3 times the OD450 of PBS controls) and used for sub-
sequent analysis.
Table  1. Number of Sera From Responders to Influenza B Virus From 
the B/Victoria-Like Lineage (B/Vic) and Influenza B Virus From the B/
Yamagata-Like Lineage (B/Yam), by Age
Variable
Responders by Age, No.
1 y 2 y 3 y 4 y 5 y 6 y 7 y
B/Vic responders 
(n = 18)
1 2 2 2 2 5 4
B/Yam responders 
(n = 23)
2 3 3 3 4 5 3
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ADCC Assay
We measured the presence of ADCC-mediating antibodies in 
serum following interaction with purified full-length recom-
binant HA from representative IBVs, B/Yamanashi/166/98 
(B/Yam) and B/Brisbane/60/08 (B/Vic, made available by 
Protein Sciences). To determine the head or stalk specificity 
of the ADCC-mediating antibodies, assays were performed 
with the HA1 subunit from B/Florida/4/06 (B/Yam) and B/
Malaysia/2506/04 (B/Vic) or with chimeric HA consisting of the 
head domain of an H8 IAV (A/mallard/Sweden/24/02) and the 
stalk of IBV B/Yamagata/16/88 (cH8/B) (Figure 1). An ADCC 
assay was performed as described previously [28]. High-binding, 
96-well, flat-bottomed plates (Immunolon) were coated over-
night at 4°C (200 ng/well), blocked, washed with a set dilution 
(1:160) of serum, and incubated at 37°C. Appropriate positive 
and negative controls were included. After 2 hours, the con-
tinuous NK cell-line NK92.05-CD16 [29] was added (1 × 105 
cells/well), and plates were incubated for 5 hours at 37°C in 
the presence of Golgistop, Golgiplug, and a human monoclo-
nal antibody (labeled with V450) directed to the degranula-
tion marker CD107a (all from BD Biosciences). Subsequently, 
cells were stained with fixable Live/Dead (Molecular Probes) 
and CD56 (labeled with PE; BD Biosciences) and acquired on 
a FACS Canto II (BD Biosciences); percentages of degranulat-
ing CD107a+ cells were determined within the respective Live-
stained CD56+ NK cell populations.
Determination of ADCC End Point Titers
ADCC end point titers were determined as described previ-
ously [28]. Sera were tested as outlined above in a 4-fold serial 
dilution series (from 1:10 to 1:163 840), and the percentages of 
CD107a+ NK92.05-CD16 cells were calculated by subtracting 
the background values obtained with mock-coated plates from 
the values obtained with HA-coated plates. The highest serum 
dilution still resulting in a population in which >5% of cells 
were CD107a+ NK92.05-CD16s, which was chosen as a cutoff, 
was recorded as the end point ADCC serum antibody titer. This 
cutoff represents the background value obtained with the nega-
tive serum pool, multiplied by ±3.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism. 
CD107a+ percentages obtained with different antigens were 
compared by performing a nonparametric Wilcoxon rank test 
or a Mann-Whitney test on paired or unpaired serum samples, 
respectively. A  nonparametric Friedman test involving paired 
samples with multiple comparisons was performed to compare 
the ELISA and ADCC data obtained with the different antigens 
in a side-by-side experiment.
RESULTS
ADCC End Point Titration and Selection of Optimal Serum Dilution
Sera obtained from 2 coworkers positive for IBV-specific HI 
antibodies were analyzed for the presence of ADCC-mediating 
antibodies against full-length HA from both IBV lineages (B/
Brisbane/60/08 and B/Yamanashi/166/98). A serum pool 
obtained from seronegative children and intravenous immu-
noglobulin (IVIG) were used as negative and positive controls, 
Table 2. Responses to Influenza A(H1N1) Virus, Influenza A(H3N2) Virus, 
Influenza B Virus From the B/Victoria-Like Lineage (B/Vic), and Influenza B 
Virus From the B/Yamagata-Like Lineage (B/Yam) Among Individuals With 
Responses to B/Vic or B/Yam
Variable
Response,a No. (%)
A(H1N1) A(H3N2) B/Vic B/Yam
B/Vic responders (n = 18) 7 (39) 14 (78) 15 (83) 0 (0)
B/Yam responders (n = 23) 11 (48) 21 (91) 0 (0) 23 (100)
B/Vic or B/Yam responders were defined on the basis of the presence of HI serum anti-
bodies against viruses of the corresponding lineage and the absence of antibodies against 
viruses of the opposing lineage. The highest HI titers obtained with representative A(H1N1), 
A(H3N2), B/Vic, and B/Yam strains from the relevant seasons are shown.
Abbreviation: Hi, hemagglutination inhibition.
aDefined as individuals with an HI titer of ≥40 to the specified influenza A or B virus.
B/Brisbane/60/08 stalk head stalk stalk
B/Yamanashi/166/98
B/Malaysia/2506/04
B/Florida/4/06
cH8/B
HA1 HA2
Figure 1. Schematic overview of hemagglutinin (HA) antigens used in the enzyme-linked immunosorbent assay and antibody-dependent cellular cytotoxicity assay. B/
Brisbane/60/08 was used as a reference sequence, and mutations relative to B/Brisbane/60/08 in the various antigens are shown in red. The cH8/B antigen contains the 
globular head of an influenza A virus of the H8 subtype, and the stalk in from B/Yamagata/16/88.
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respectively. End point B/Vic- and B/Yam-specific ADCC titers 
were determined by creating 4-fold serial dilutions of serum 
samples; an arbitrary cutoff (end point) for presence of ADCC-
mediating antibodies was set at 5% CD107a+ NK92.05-CD16 
cells (Supplementary Figure 1A and 1B). At a 1:10 dilution and 
occasionally at dilutions of 1:40 and 1:160, lower percentages of 
CD107a+ cells were observed than at higher dilutions, indicative 
of a prozonal effect. B/Vic- and B/Yam-specific ADCC-mediating 
antibodies were in general equally present and detected with sim-
ilar CD107a+ percentages at a set dilution and end point titers 
(Supplementary Figure 1A and 1B). Since, at a 1:160 serum dilu-
tion, CD107a+ NK cells were readily detected with minimal pro-
zonal effects, this dilution was chosen for subsequent experiments.
First-Time IBV Infection of Children Induces ADCC-Mediating Antibodies
Sera from 41 pediatric subjects aged 1–7 years with serological 
evidence of first-time exposure to IBV of either lineage were 
selected (Table 1). Based on HI data that were generated with 
various epidemic IBV strains that these subjects had potentially 
been exposed to [25], sera from subjects with evidence of infec-
tion with the B/Vic (n  =  18) or B/Yam (n  =  23) lineage were 
identified (B/Vic or B/Yam responders, respectively; Table 2). All 
subjects had detectable HI titers against ≥1 epidemic IBV strains 
from a single lineage, but not all subjects reached HI titers of 
≥40. In addition, most subjects had A(H1N1)- and A(H3N2)-
specific HI antibodies, indicating that they had experienced 1 or 
multiple IAV infections (Figure 2A and 2B show the highest HI 
titers obtained with representative IAV and IBV strains).
The presence of ADCC-mediating antibodies directed to the 
HA of either IBV lineage in B/Vic and B/Yam responders was 
determined by a solid-phase ADCC assay, using representative 
full-length HAs from both IBV lineages (ie, B/Brisbane/60/08 [B/
Vic] and B/Yamanashi/166/98 [B/Yam]) as antigens. Significant 
levels of HA-specific ADCC-mediating antibodies reactive with 
B/Vic and B/Yam HA were detected in B/Vic responders and B/
Yam responders, respectively (P <  .0001), indicating that infec-
tion induced ADCC-mediating antibodies specific for HA of the 
corresponding lineage (Figure  3A and 3B). In both B/Vic and 
B/Yam responders, limited correlation was observed between 
ADCC and HI antibody titers directed to IBV of the homologous 
lineage (the slopes were significantly different from 0; Figure 3A 
and 3B). Interestingly, ADCC activity to HA of the heterologous 
IBV lineage was also detected; the ADCC activity to HA of B/Yam 
was detected in B/Vic responders (P < .0001; Figure 3A), and the 
ADCC activity to HA of B/Vic was detected in B/Yam responders 
(P < .0001; Figure 3B). ADCC activity to HA of the heterologous 
lineage was significantly lower than to that of the correspond-
ing lineage for both B/Vic (P  =  .0022; Figure  3A) and B/Yam 
(P  =  .0136; Figure  3B) responders. Notably, these HA-specific 
cross-reactive ADCC-mediating antibodies were detected in the 
absence of HI antibodies against the heterologous lineage.
IBV Infection Induces HA Head–Specific and HA Stalk–Specific 
Antibodies
To determine whether IBV infection induced antibodies spe-
cific to the HA head and/or stalk, we performed an ELISA to 
assess the presence of serum antibodies to full-length HA and 
the HA1 subunit of both lineages or a chimeric HA (represent-
ing the IBV stalk only). Representative full-length HAs (B/
Brisbane/60/08 [B/Vic] and B/Yamanashi/166/98 [B/Yam]) and 
representative HA1 subunits (B/Malaysia/2506/04 [B/Vic] and 
B/Florida/04/06 [B/Yam]) from both IBV lineages were used as 
antigens. The chimeric HA consisted of the head domain of an 
irrelevant IAV (H8 subtype) and the stalk domain of IBV B/
B/Vic responders (n = 18) B/Yam responders (n = 23)
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Figure 2. Influenza A virus (IAV)– and influenza B virus (IBV)–specific hemagglutination inhibition (HI) responses in selected subjects. HI titers against representative influ-
enza A(H1N1), influenza A(H3N2), influenza B/Vic, and influenza B/Yam viruses circulating in the relevant seasons were determined for 41 selected subjects in the scope of 
another study. Subjects were categorized as B/Vic (n = 18; A) or B/Yam (n = 23; B) responders. A, HI antibodies against B/Vic were detected in all responders; 15 of 18 subjects 
reached HI titers of ≥40. HI titers of ≥40 specific for B/Yam were not detected. B, HI antibodies against B/Yam were detected in 23 of 23 subjects; all reached HI titers of ≥40. 
HI titers of ≥40 specific for B/Vic were not detected.
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Yamagata/16/88 (cH8/B) (Figure 1). Since humans presumably 
do not possess antibodies to IAV of the H8 subtype, cH8/B-re-
active antibodies are likely specific for the IBV HA stalk.
In both B/Vic and B/Yam responders, antibodies recogniz-
ing the corresponding full-length HA were detected by ELISA 
(P < .0001 for both comparisons; Figure 4A and 4B). Antibodies 
reactive with heterologous full-length HAs were also detected 
in both responder groups (P  <  .0001 for both comparisons), 
indicating the presence of antibodies that react across both 
IBV lineages. However, when the HA1 subunit was used as 
antigen, antibodies reactive with HA1 of the corresponding 
lineage (P <  .0001 for both comparisons) were predominantly 
detected, and reactivity with HA1 of the opposing lineage was 
not detected (P  >  .9999 and P  =  .4509 for B/Vic and B/Yam 
responders, respectively). HA stalk–specific antibodies were 
detected in both B/Vic and B/Yam responders (P =  .0288 and 
P = .0137, respectively), indicating that HA stalk–specific anti-
bodies were likely responsible for the cross-reactivity observed 
against the full-length HA of the opposing IBV lineage. ELISA 
titers obtained with the HA1 subunit of the corresponding IBV 
lineage correlated with HI titers but not with those obtained 
with HA1 of the opposing lineage or cH8/B in both the B/Vic 
and B/Yam responders (data not shown).
HA Stalk–Specific Antibodies Are Responsible for ADCC
To resolve the specificity of cross-reactive ADCC, ADCC reac-
tivity to the HA stalk, HA1 subunits, or full-length HAs was 
determined. Concordant with results of ELISA and the ADCC 
assays (Figure 3), ADCC activity cross-reactive with full-length 
HA of the opposing lineage was detected in both B/Vic and 
B/Yam responders (P  <  .0001 for all comparisons between 
full-length HA and mock; Figure 4C and 4D). Although anti-
bodies reactive with the homologous HA1 were detected by 
ELISA, these antibodies failed to mediate ADCC to the HA1 
of the corresponding and opposing IBV lineage in both B/Vic 
responders (P > .9999 and P > .9999, respectively) and B/Yam 
responders (P  =  .2023 and P  =  .3494, respectively), although 
limited reactivity with the B/Yam HA1 subunit was detected in 
B/Yam responders. In contrast, ADCC-mediating antibodies 
were readily detected to cH8/B in both B/Vic (P <  .0001) and 
B/Yam (P =  .0035) responders, indicating that ADCC activity 
was predominantly specific for the HA stalk. HA stalk–specific 
ADCC activity correlated significantly with ELISA end point 
titers and OD450 values measured with cH8/B (data not shown). 
In conclusion, infection of pediatric subjects with IBV of the B/
Vic or B/Yam lineage induced both HA head–specific and HA 
stalk–specific antibodies, but only HA stalk–speciﬁc antibodies 
were capable of mediating ADCC across the 2 lineages of IBV.
DISCUSSION
Here, we assessed whether human infections with IBV induced 
ADCC-mediating antibodies and determined the cross-reactiv-
ity of these antibodies with IBV of the 2 antigenically distinct 
IBV lineages. To this end, serum samples obtained from chil-
dren 1–7 years of age with serological evidence of having experi-
enced an infection with IBV of either lineage were tested for the 
presence of IBV-specific ADCC activity. Infection of pediatric 
subjects with IBV of either the B/Vic or B/Yam lineage induced 
ADCC-mediating antibodies that were specific for HA of the 
corresponding lineage and that displayed cross-reactivity with 
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Figure 3. Hemagglutinin (HA)–specific antibody-dependent cellular cytotoxicity 
(ADCC)–mediating antibodies after primary influenza B virus (IBV) infection. ADCC 
responses against a representative B/Vic antigen (B/Brisbane/60/08; A) and a rep-
resentative B/Yam antigen (B/Yamanashi/166/98; B) were determined in both B/Vic 
and B/Yam responder sera. A, Statistically significantly higher CD107a+ percentages 
were detected after stimulation with B/Vic in both the B/Vic and B/Yam respond-
ers as compared to the phosphate-buffered saline (PBS) control (left panel). B/Vic-
specific responses were significantly higher in the B/Vic responders as compared 
to the B/Yam responders. Correlation between B/Vic hemagglutination inhibition 
(HI) titers and ADCC percentages (right panel). B, Statistically significantly higher 
CD107a+ percentages were detected after stimulation with B/Yam in both the B/Vic 
and B/Yam responders as compared to the PBS control (left panel). B/Yam-specific 
responses were significantly higher in the B/Yam responders as compared to the B/
Vic responders. Correlation between B/Yam HI titers and ADCC percentages (right 
panel). CD107a+ percentages obtained with different antigens were compared by 
performing a nonparametric Wilcoxon rank test or Mann-Whitney test on paired or 
unpaired serum samples, respectively.
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HA of IBV from the opposing lineage. IBV infection induced 
both HA head–specific and HA stalk–specific binding antibod-
ies as demonstrated by ELISA, but interestingly, only HA stalk–
specific antibodies were capable of mediating ADCC.
First time infection with 2009 pandemic influenza A(H1N1) 
virus was previously shown to induce ADCC-mediating anti-
bodies in children [28, 30], using paired preinfection and post-
infection serum samples. Here, we used selected serum samples 
from young children who tested positive by HI for the pres-
ence of antibodies to IBV belonging to one of the phylogenetic 
lineages, B/Yam or B/Vic. These serum samples, obtained after 
primary IBV infection, were tested for the presence of ADCC-
mediating antibodies. Similar to infection with IAV [28, 30], 
infection with IBV induced ADCC activity, which correlated 
with HI antibody titers to a limited extent.
The selected serum samples were obtained from 41 pediatric 
subjects, selected for presence of serum antibodies to IBV of a 
single lineage. Eighteen of these subjects were identified to be 
infected with an IBV of the B/Vic lineage, and 23 were infected 
with IBV of the B/Yam lineage. Of note, it has been shown that HI 
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Figure 4. Detection of antibody-dependent cellular cytotoxicity [ADCC]–mediating hemagglutinin (HA) stalk–specific and HA head–specific antibodies after primary influ-
enza B virus (IBV) infection. A and B, Antibodies against either the full-length (FL) HA of both lineages, the HA1 of both lineages, or the HA stalk (cHA, chimeric HA) after a 
primary IBV infection were detected by enzyme-linked immunosorbent assay (ELISA). End point titers were determined by creating 5-fold serial dilutions of serum samples, 
and a cutoff (end point) for the presence of specific antibodies was set at 3 times the background level. Statistically significantly higher end point titers were detected against 
the full-length HA of both lineages, the homologous HA1 subunit, and the HA stalk as compared to the phosphate-buffered saline (PBS) control. C and D, Presence of ADCC-
mediating antibodies against either the full-length HA of both lineages, the HA1 of both lineages, or the HA stalk after a primary IBV infection. Statistically significantly 
higher CD107a+ were detected upon stimulation with the full-length HA of both lineages and the HA stalk as compared to the PBS control. Stimulation with the HA1 subunit 
only, homologous or heterologous, did not lead to significant differences as compared to the PBS control. A nonparametric Friedman test on paired samples with multiple 
comparisons was performed to compare the ELISA and ADCC data obtained with the different antigens.
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antibodies to IBV of one lineage fail to react with an IBV of the 
opposing lineage [7, 25]. Since the HI assay only detects antibod-
ies directed to epitopes located in or near the receptor binding 
site of HA, we performed ELISA with full-length HA, the HA1 
subunit, or chimeric HA cH8/B to demonstrate that primary IBV 
infection induced antibodies reactive with both the HA head and 
stalk. Cross-lineage reactive antibodies were detected by ELISA 
and proved to be mainly directed to the HA stalk. To determine 
whether HA-specific ADCC-mediating antibodies cross-reacted 
with IBV from the opposing lineage, sera from B/Vic responders 
were tested for B/Yam-specific ADCC activity, and sera from B/
Yam responders were tested for B/Vic-specific ADCC activity. 
Of interest, cross-lineage ADCC activity was observed both in 
B/Vic responders and B/Yam responders and was found to be 
exclusively mediated by stalk-specific antibodies. Notably, the 
full-length HA and HA1 subunit used in these assays did not 
fully antigenically match the IBV strain to which subjects were 
exposed, owing to the availability of antigens and variation in the 
IBV strains. Representative antigens, antigenically close to the 
viruses the subjects were infected with, were therefore chosen.
Interestingly, HA head–specific antibodies present in human 
sera failed to mediate ADCC after binding to their epitopes 
located in the HA head domain of IBV of the corresponding (or 
opposing) lineage. This corresponds to recent findings, showing 
that monoclonal antibodies that interfere with binding of HA to 
sialic acid molecules on NK cells are not capable of mediating 
ADCC. It has been hypothesized that the interaction between 
Fc and FcγRIIIα alone is not enough to mediate FcγRIIIα acti-
vation and that the additional interaction, between HA and 
sialic acid, is required to possibly stabilize the immunological 
synapse between target and effector cell for efficient ADCC 
[31–33]. Here we show in human polyclonal sera that antibod-
ies to the stalk region and not those specific for the HA head are 
responsible for ADCC. Notably, the HA1 subunit used in the 
assays described here also contains part of the stalk, potentially 
explaining the ADCC reactivity detected against the HA1 from 
the B/Yam lineage in the B/Yam responders. Furthermore, we 
show that, in the solid-phase ADCC assay and with the use of 
NK92.05-CD16 cells, 2 points of contact between effector cells 
and HA are still required for ADCC activity.
The induction of HA stalk–specific antibodies has gained con-
siderable interest as universal vaccination approach against IAV 
[34–37]. Monoclonal antibodies directed to the HA stalk have 
broad reactivity and are capable of inducing protection from 
challenge with IAV of various subtypes in animal models. This 
protection is predominantly conferred by Fcγ receptor–depen-
dent mechanisms [19, 38, 39]. Monoclonal antibodies recogniz-
ing conserved IBV epitopes have also been identified [40, 41]. 
One of these is broadly reactive, of the IgG1 subclass (46B8), 
and proved capable of neutralizing IBV from both lineages [42]. 
46B8 mediated ADCC in vitro and was capable of protecting 
mice from lethal IBV challenge. An Fc-defective variant of 
46B8 did not confer protection from challenge, demonstrating 
that Fcγ receptor–dependent mechanisms were crucial in this 
model. Novel universal IBV vaccination approaches focus on 
the induction of HA stalk–specific antibodies; sequential vac-
cination of mice with chimeric HAs consisting of the globu-
lar head domains from irrelevant IAVs and stalks from IBVs 
induced HA stalk–specific antibodies was performed, confer-
ring protection from challenge with multiple IBVs from both 
lineages [27]. Notably, ADCC was identified as the most likely 
correlate of protection in these experiments.
Collectively, the data presented here show that initial IBV infec-
tion of children induces both HA head–specific and HA stalk–
specific antibodies. The HA head–specific antibodies (as detected 
by HI and ELISA) bind to IBV of the corresponding lineage only, 
whereas HA stalk–specific antibodies recognized IBV of the cor-
responding and opposing lineages. Interestingly, HA head–spe-
cific antibodies did not mediate ADCC upon binding to HA, but 
HA stalk–specific antibodies did. This could be explained by the 
hypothesis that 2 points of contact between target and effector cell 
are required for efficient ADCC and that HA head–specific anti-
bodies potentially disrupt the interaction between HA and sialic 
acid. Altogether, this study demonstrates that human infection 
with IBV induces ADCC-mediating antibodies mainly directed 
to the HA stalk of IBV, which display cross-reactivity with IBV of 
both lineages. These ADCC-mediating antibodies might afford a 
certain degree of cross-protection from infection with antigeni-
cally distinct IBV, but the minimal requirements for protection 
remain to be determined.
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